XML 8 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 2,203 $ 3,300
Accounts receivables, net of allowance for credit losses of $82 million and $78 million as of September 30, 2025 and December 31, 2024, respectively. 3,810 3,059
Inventories 3,323 3,007
Prepaid expenses 1,115 1,006
Other current assets 477 409
Assets held for sale 1,809 1,771
Total current assets 12,736 12,552
Deferred income taxes 1,634 1,799
Other non-current assets 444 462
Property, plant and equipment, net 4,820 4,581
Operating lease right-of-use assets, net 342 367
Identifiable intangible assets, net 3,936 4,418
Goodwill [1] 15,945 15,147
Total assets 39,856 39,326
Current liabilities:    
Short-term debt 24 1,781
Sales reserves and allowances 4,134 3,678
Accounts payables 2,355 2,203
Employee-related obligations 561 624
Accrued expenses 2,989 2,792
Other current liabilities 1,103 1,020
Liabilities held for sale 324 698
Total current liabilities 11,491 12,796
Long-term liabilities:    
Deferred income taxes 399 483
Other taxes and long-term liabilities 3,664 4,028
Senior notes and loans 16,766 16,002
Operating lease liabilities 283 296
Total long-term liabilities 21,111 20,809
Commitments and contingencies, see note 10
Total liabilities 32,602 33,606
Redeemable non-controlling interests 0 340
Teva shareholders' equity:    
Ordinary shares of NIS 0.10 par value per share; September 30, 2025 and December 31, 2024: authorized 2,495 million shares; issued 1,253 million shares and 1,240 million shares, respectively. 58 58
Additional paid-in capital 28,038 27,764
Accumulated deficit (14,243) (15,173)
Accumulated other comprehensive loss (2,475) (3,148)
Treasury shares as of September 30, 2025 and December 31, 2024: 106 million and 107 million ordinary shares, respectively. (4,128) (4,128)
Stockholders' equity attributable to Teva shareholders 7,250 5,373
Non-controlling interests 4 7
Total equity 7,254 5,380
Total liabilities, redeemable non-controlling interests and equity $ 39,856 $ 39,326
[1] Cumulative goodwill impairment as of September 30, 2025 and December 31, 2024, was each approximately $29.6 billion.